BREAKWATER: Randomized phase 3 study of encorafenib (enco) plus cetuximab (cetux) +/- chemotherapy for first-line (1L) treatment (tx) of BRAF V600E-mutant (BRAF(V600E)) metastatic colorectal cancer (mCRC)
Kopetz, S., Grothey, A., Yaeger, R., Ciardiello, F., Desai, J., Kim, T. W., . . . Tabernero, J. (2021). BREAKWATER: … Read More
